Author
Eisen Gen
Bio: Eisen Gen is an academic researcher from Showa University. The author has contributed to research in topics: Nucleoside & Pivalic acid. The author has an hindex of 4, co-authored 6 publications receiving 89 citations.
Topics: Nucleoside, Pivalic acid, Uracil, Glycal, Uridine
Papers
More filters
56 citations
TL;DR: In this article, the 6-tributylstannyl (or 6-trimethylsilyl) derivative prepared by quenching the C6-lithiated species with Bu3SnCl (or Me3SiCl) was found to undergo an intramolecular anionic migration to the 2′-posposition of the furanoid glycal portion.
14 citations
11 citations
TL;DR: In this article, it was shown that TBDMS-protected 1-(2-deoxy-D- erythro -pent-1-enofuranosyl)-6-(tributyl-stannyl)uracil, when treated with LDA or LTMP, undergoes an anionic stannyl migration to yield the 2′-staned product.
6 citations
TL;DR: Compounds 5b and 5c were shown to serve as versatile synthons for the respective 2′-C-branched 1′,2′-unsaturated uracil nucleosides, through palladium-catalyzed cross-coupling or halogen-lithium exchange reactions.
Abstract: An alternative method for the preparation of 2′-bromo- (5b) and 2′-iodo- (5c) 1′,2′-unsaturated uracil nucleosides has been developed. The protocol was on the basis of the syn-elimination o...
2 citations
Cited by
More filters
Patent•
23 May 2001
TL;DR: A method and composition for treating a host infected with hepatitis C comprising administering an effective hepatitis C treatment amount of a described 1′, 2′ or 3′-modified nucleoside or a pharmaceutically acceptable salt or prodrug thereof, is provided in this paper.
Abstract: A method and composition for treating a host infected with hepatitis C comprising administering an effective hepatitis C treatment amount of a described 1′, 2′ or 3′-modified nucleoside or a pharmaceutically acceptable salt or prodrug thereof, is provided.
248 citations
Patent•
23 May 2001TL;DR: In this article, a method and composition for treating a host infected with a pest or a flavivirus comprising administering an effective flavivirirus or pestivirus treatment amount of a described 1′, 2′ or 3′ modified nucleoside or a pharmaceutically acceptable salt or prodrug thereof, is provided.
Abstract: A method and composition for treating a host infected with flavivirus or pestivirus comprising administering an effective flavivirus or pestivirus treatment amount of a described 1′, 2′ or 3′-modified nucleoside or a pharmaceutically acceptable salt or prodrug thereof, is provided.
180 citations
Patent•
06 Dec 2004TL;DR: In this article, 2.2 and/or 3.2-branched nucleoside prodrugs of 1.2, 2.5, 3.5 and 4.5-branched nucleosides are described.
Abstract: 2′ and/or 3′ prodrugs of 1′, 2′, 3′ or 4′-branched nucleosides, and their pharmaceutically acceptable salts and derivatives are described. These prodrugs are useful in the prevention and treatment of Flaviviridae infections, including HCV infection, and other related conditions. Compounds and compositions of the prodrugs of the present invention are described. Methods and uses are also provided that include the administration of an effective amount of the prodrugs of the present invention, or their pharmaceutically acceptable salts or derivatives. These drugs may optionally be administered in combination or alteration with further anti-viral agents to prevent or treat Flaviviridae infections and other related conditions.
151 citations
Patent•
27 Jun 2003
TL;DR: The 3′-L-valine ester of β-D-2′-C-methyl-ribofuranosyl cytidine provides superior results against flavivirus and pestivirus, including hepatitis C virus as discussed by the authors.
Abstract: The 3′-L-valine ester of β-D-2′-C-methyl-ribofuranosyl cytidine provides superior results against flaviviruses and pestiviruses, including hepatitis C virus. Based on this discovery, compounds, compositions, methods and uses are provided for the treatment of flaviviridae, including HCV, that include the administration of an effective amount of val-mCyd or its salt, ester, prodrug or derivative, optionally in a pharmaceutically acceptable carrier. In an alternative embodiment, val-mCyd is used to treat any virus that replicates through an RNA-dependent RNA polymerase.
136 citations
Patent•
13 Apr 2001
TL;DR: In this article, a composition for and a method of treating hepatitis B virus (HBV) infection, hepatitis C virus (HCV), hepatitis D virus (HDV), or a proliferative disorder in a patient using an effective amount of a compound selected from the group consisting of formulas (I)-(IV) below and mixtures of two or more thereof, wherein the substituents are as defined herein.
Abstract: The present invention relates to a composition for and a method of treating hepatitis B virus (HBV) infection, hepatitis C virus (HCV) infection, hepatitis D virus (HDV) infection or a proliferative disorder in a patient using an effective amount of a compound selected from the group consisting of formulas (I)-(IV) below and mixtures of two or more thereof, wherein the substituents are as defined herein. Pharmaceutical compositions comprising these compounds in combination with other HBV, HCV, or HDV agents is also disclosed.
116 citations